TY - JOUR
T1 - Persistent negative symptoms in first episode patients with schizophrenia
T2 - Results from the European First Episode Schizophrenia Trial
AU - Galderisi, Silvana
AU - Mucci, Armida
AU - Bitter, Istvan
AU - Libiger, Jan
AU - Bucci, Paola
AU - Wolfgang Fleischhacker, W.
AU - Kahn, René S.
AU - Fleischhacker, W. W.
AU - Boter, H.
AU - Keet, I. P.M.
AU - Brugman, C.
AU - Davidson, M.
AU - Dollfus, S.
AU - Gaebel, W.
AU - Gheorghe, M.
AU - Gonen, I.
AU - Grobbee, D. E.
AU - Hranov, L. G.
AU - Hummer, M.
AU - Lindefors, N.
AU - López-Ibor, J. J.
AU - Nijssen, K.
AU - Peuskens, J.
AU - Prelipceanu, D.
AU - Riecher-Rössler, A.
AU - Rybakowski, J. K.
AU - Sedvall, G.
AU - Von Wilmsdorff, M.
N1 - Funding Information:
WWF has received research grants from Alkermes, BMS/Otsuka, Eli Lilly, Janssen-Cilag, and Pfizer; speaking fees from BMS/Otsuka, Janssen-Cilag, Lundbeck and Pfizer; and advisory board honoraria from Amgen, BMS/Otsuka, Endo, Janssen-Cilag, MedAvante, Richter Targacept and Neurosearch. He holds MedAvante stock.
Funding Information:
EUFEST was funded by the European Group for Research in Schizophrenia (EGRIS) with grants from AstraZeneca, Pfizer, and Sanofi-Aventis. As to the present study, neither EGRIS nor any sponsor had any further role in the data analysis and interpretation; in the writing of the report; and in the decision to submit the paper for publication.
PY - 2013/3/1
Y1 - 2013/3/1
N2 - Negative symptoms that do not improve following antipsychotic treatment represent a challenge for development of effective treatments. Few studies have been carried out so far, especially in first-episode schizophrenia patients, to clarify prevalence, correlates and impact of persistent negative symptoms (PNS) on short- and long-term outcome of the disease.All patients from EUFEST study for whom both baseline and 12-month assessments were available were included (N=345). PNS were defined as the presence of at least one negative symptom of moderate or higher severity, not confounded by depression or parkinsonism, at baseline and after 1 year of treatment. Patients with PNS were compared to those with at least one negative symptom of moderate or higher severity at the baseline, not persisting after 1 year, on demographic, clinical, neurocognitive, global functioning and quality of life measures.PNS not confounded by depression or parkinsonism were present in 6.7% of the sample. The symptom that more often persisted was blunted affect. Patients with PNS differed from those without PNS for a longer duration of untreated psychosis (DUP) and a more frequent discontinuation of study treatment; they also had a poorer psychopathological outcome and a worse global functioning after 1 year of treatment.The presence of PNS was associated to poorer improvement of all psychopathological dimensions and worse global functioning after 1 year of treatment. The longer DUP in subjects with PNS suggests that programs aimed at shortening DUP might reduce the prevalence of PNS and improve prognosis of schizophrenia.
AB - Negative symptoms that do not improve following antipsychotic treatment represent a challenge for development of effective treatments. Few studies have been carried out so far, especially in first-episode schizophrenia patients, to clarify prevalence, correlates and impact of persistent negative symptoms (PNS) on short- and long-term outcome of the disease.All patients from EUFEST study for whom both baseline and 12-month assessments were available were included (N=345). PNS were defined as the presence of at least one negative symptom of moderate or higher severity, not confounded by depression or parkinsonism, at baseline and after 1 year of treatment. Patients with PNS were compared to those with at least one negative symptom of moderate or higher severity at the baseline, not persisting after 1 year, on demographic, clinical, neurocognitive, global functioning and quality of life measures.PNS not confounded by depression or parkinsonism were present in 6.7% of the sample. The symptom that more often persisted was blunted affect. Patients with PNS differed from those without PNS for a longer duration of untreated psychosis (DUP) and a more frequent discontinuation of study treatment; they also had a poorer psychopathological outcome and a worse global functioning after 1 year of treatment.The presence of PNS was associated to poorer improvement of all psychopathological dimensions and worse global functioning after 1 year of treatment. The longer DUP in subjects with PNS suggests that programs aimed at shortening DUP might reduce the prevalence of PNS and improve prognosis of schizophrenia.
KW - Cognitive functioning
KW - Duration of untreated psychosis
KW - Global functioning
KW - Quality of life
KW - Remission
UR - http://www.scopus.com/inward/record.url?scp=84875268666&partnerID=8YFLogxK
U2 - 10.1016/j.euroneuro.2012.04.019
DO - 10.1016/j.euroneuro.2012.04.019
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 22647933
AN - SCOPUS:84875268666
SN - 0924-977X
VL - 23
SP - 196
EP - 204
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
IS - 3
ER -